Page 6 - Registry Study News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Cara Therapeutics and Vifor Pharma announce U.S. FDA acceptance and Priority Review of NDA for ... Cara Therapeutics, Inc.March 8, 2021 GMT FDA has set Prescription Drug User Fee Act (PDUFA) target action date of August 23, 2021 If approved, KORSUVA™ injection would be first therapy for treatment of pruritus in hemodialysis patients STAMFORD, Conn, and ST. GALLEN, Switzerland, March 08, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics (Nasdaq:CARA) and Vifor Pharma today announced that the U.S. Food a...

TMCnet News Cara Therapeutics Submits New Drug Application to U.S. Food and Drug Administration for KORSUVA™ Injection in Hemodialysis Patients with Moderate-to-Severe Pruritus [December 28, 2020] Cara Therapeutics Submits New Drug Application to U.S. Food and Drug Administration for KORSUVA™ Injection in Hemodialysis Patients with Moderate-to-Severe Pruritus First NDA submission for Company’s lead program, KORSUVA™ Injection – NDA submission includes request for Priority Review under Breakthrough Therapy Designation for KORSUVA Injection – STAMFORD, Conn., Dec. 28, 20...